Phio Pharmaceuticals Corp (PHIO) - Net Assets
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has net assets worth $16.46 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.41 Million) and total liabilities ($950.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Phio Pharmaceuticals Corp to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.46 Million |
| % of Total Assets | 94.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | -8.14% |
| 10-Year Change | 85.6% |
| Growth Volatility | 204.91 |
Phio Pharmaceuticals Corp - Net Assets Trend (2011–2025)
This chart illustrates how Phio Pharmaceuticals Corp's net assets have evolved over time, based on quarterly financial data. See Phio Pharmaceuticals Corp liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual net assets of Phio Pharmaceuticals Corp from 2011 to 2025. For live valuation and market cap data, see Phio Pharmaceuticals Corp (PHIO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $20.15 Million | +326.57% |
| 2024-12-31 | $4.72 Million | -38.90% |
| 2023-12-31 | $7.73 Million | -28.69% |
| 2022-12-31 | $10.84 Million | -50.57% |
| 2021-12-31 | $21.93 Million | +68.49% |
| 2020-12-31 | $13.02 Million | +126.46% |
| 2019-12-31 | $5.75 Million | -57.67% |
| 2018-12-31 | $13.58 Million | +640.75% |
| 2017-12-31 | $1.83 Million | -83.11% |
| 2016-12-31 | $10.86 Million | +22.10% |
| 2015-12-31 | $8.89 Million | +223.86% |
| 2014-12-31 | $2.75 Million | -44.46% |
| 2013-12-31 | $4.94 Million | +184.62% |
| 2012-12-31 | $-5.84 Million | -894.89% |
| 2011-12-31 | $-587.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phio Pharmaceuticals Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15077700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $175.20 Million | 869.61% |
| Total Equity | $20.15 Million | 100.00% |
Phio Pharmaceuticals Corp Competitors by Market Cap
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NFL Biosciences SAS
PA:ALNFL
|
$12.55 Million |
|
Lanthanein Resources Ltd
AU:LNR
|
$12.55 Million |
|
Personas Social Inc
V:PRSN
|
$12.56 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
$12.60 Million |
|
Hawsons Iron Ltd
AU:HIO
|
$12.54 Million |
|
E-Starco
KO:015020
|
$12.54 Million |
|
Draper Esprit PLC
LSE:GROW
|
$12.54 Million |
|
Magna Terra Minerals Inc
V:MTT
|
$12.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phio Pharmaceuticals Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,723,000 to 20,147,000, a change of 15,424,000 (326.6%).
- Net loss of 8,698,000 reduced equity.
- New share issuances of 17,915,000 increased equity.
- Other factors increased equity by 6,207,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.70 Million | -43.17% |
| Share Issuances | $17.91 Million | +88.92% |
| Other Changes | $6.21 Million | +30.81% |
| Total Change | $- | 326.57% |
Book Value vs Market Value Analysis
This analysis compares Phio Pharmaceuticals Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-74492.39 | $1.08 | x |
| 2012-12-31 | $-657657.66 | $1.08 | x |
| 2013-12-31 | $250101.21 | $1.08 | x |
| 2014-12-31 | $74269.48 | $1.08 | x |
| 2015-12-31 | $80899.08 | $1.08 | x |
| 2016-12-31 | $95689.35 | $1.08 | x |
| 2017-12-31 | $4828.51 | $1.08 | x |
| 2018-12-31 | $11471.88 | $1.08 | x |
| 2019-12-31 | $1348.54 | $1.08 | x |
| 2020-12-31 | $306.77 | $1.08 | x |
| 2021-12-31 | $184.79 | $1.08 | x |
| 2022-12-31 | $85.92 | $1.08 | x |
| 2023-12-31 | $33.39 | $1.08 | x |
| 2024-12-31 | $6.00 | $1.08 | x |
| 2025-12-31 | $3.37 | $1.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phio Pharmaceuticals Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-43.17%) is above the historical average (-159.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.16 Million |
| 2012 | 0.00% | -13278.35% | 0.02x | 0.00x | $-12.30 Million |
| 2013 | -423.41% | -5244.36% | 0.03x | 3.02x | $-21.42 Million |
| 2014 | -320.58% | -12394.37% | 0.01x | 3.35x | $-9.07 Million |
| 2015 | -114.99% | -30067.65% | 0.00x | 1.26x | $-11.11 Million |
| 2016 | -82.86% | -47336.84% | 0.00x | 1.23x | $-10.08 Million |
| 2017 | -679.32% | -83013.33% | 0.00x | 2.24x | $-12.64 Million |
| 2018 | -54.21% | -5333.33% | 0.01x | 1.13x | $-8.72 Million |
| 2019 | -153.81% | -42100.00% | 0.00x | 1.40x | $-9.42 Million |
| 2020 | -67.56% | -201604.77% | 0.00x | 1.21x | $-10.10 Million |
| 2021 | -60.24% | 0.00% | 0.00x | 1.15x | $-15.41 Million |
| 2022 | -104.29% | 0.00% | 0.00x | 1.18x | $-12.39 Million |
| 2023 | -140.05% | 0.00% | 0.00x | 1.21x | $-11.60 Million |
| 2024 | -151.39% | 0.00% | 0.00x | 1.21x | $-7.62 Million |
| 2025 | -43.17% | 0.00% | 0.00x | 1.07x | $-10.71 Million |
Industry Comparison
This section compares Phio Pharmaceuticals Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phio Pharmaceuticals Corp (PHIO) | $16.46 Million | 0.00% | 0.06x | $12.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more